Cladribine Intravenous and Insulin aspart, recombinant Subcutaneous
Determining the interaction of Cladribine Intravenous and Insulin aspart, recombinant Subcutaneous and the possibility of their joint administration.
No interaction was detected between the selected drugs or effects of joint drug administration are currently understudied, and it takes time and accumulated statistics to determine their interaction. A doctor should be consulted to address the issue of joint drug administration.
Generic Name: cladribine
Brand name: Mavenclad, Leustatin
Synonyms: Cladribine
Generic Name: insulin aspart
Brand name: Fiasp, NovoLog, NovoLog FlexPen, NovoLog PenFill, NovoLOG FlexTouch, Fiasp PenFill, Fiasp FlexTouch
Synonyms: Insulin aspart, Insulin Aspart
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Cladribine Intravenous-Insulin degludec
- Cladribine Intravenous-Insulin Degludec (U-100) Prefilled Pens
- Cladribine Intravenous-Insulin Degludec (U-100) Vials
- Cladribine Intravenous-Insulin Degludec (U-200) Prefilled Pens
- Cladribine Intravenous-Insulin degludec and liraglutide
- Cladribine Intravenous-Insulin degludec and liraglutide Subcutaneous
- Insulin aspart, recombinant Subcutaneous-Cladribine Tablets
- Insulin aspart, recombinant Subcutaneous-Claforan
- Insulin aspart, recombinant Subcutaneous-Claforan in D5W
- Insulin aspart, recombinant Subcutaneous-Claravis
- Insulin aspart, recombinant Subcutaneous-Clarifoam EF
- Insulin aspart, recombinant Subcutaneous-Clarinex